444583-13-5 Usage
Molecular structure
2-(2-(tert-Butoxycarbonyl)isoindolin-1-yl)acetic acid is a complex organic compound with a unique molecular structure.
Protected form of amino acid
The presence of the tert-Butoxycarbonyl group makes 2-(2-(tert-Butoxycarbonyl)isoindolin-1-yl)acetic acid a protected form of an amino acid, which provides stability and utility in synthetic reactions.
Steric and electronic effects
The isoindolin-1-yl group adds steric and electronic effects to the molecule, which influences its reactivity and properties.
Carboxylic acid functionality
As a derivative of acetic acid, 2-(2-(tert-Butoxycarbonyl)isoindolin-1-yl)acetic acid possesses carboxylic acid functionality, making it suitable for use in organic synthesis and pharmaceutical research.
Value in drug and material development
The unique properties and reactivity of 2-(2-(tert-Butoxycarbonyl)isoindolin-1-yl)acetic acid make it valuable in the design and development of new drugs and materials.
Check Digit Verification of cas no
The CAS Registry Mumber 444583-13-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,4,5,8 and 3 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 444583-13:
(8*4)+(7*4)+(6*4)+(5*5)+(4*8)+(3*3)+(2*1)+(1*3)=155
155 % 10 = 5
So 444583-13-5 is a valid CAS Registry Number.
InChI:InChI=1/C15H19NO4/c1-15(2,3)20-14(19)16-9-10-6-4-5-7-11(10)12(16)8-13(17)18/h4-7,12H,8-9H2,1-3H3,(H,17,18)
444583-13-5Relevant articles and documents
COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
-
Page/Page column 87; 88, (2014/01/09)
The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Piperazine- and piperidine-derivatives as melanocortin receptor agonists
-
Page/Page column 52-53, (2010/02/06)
The present invention relates to melanocortin receptor agonists of formula I, which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction.
